
AbbVie's Skyrizi beats IL-23 rivals to Crohn's disease appro...
AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new ind